AbCellera initiates Phase 1 trial for ABCL575 assessing safety in healthy participants
AbCellera Biologics has launched Phase 1 trial to evaluate the safety and tolerability of ABCL575 in healthy volunteers.
Asset / Drug
Drug and asset intelligence for ABCL575 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Monoclonal Antibody
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.